Drugs for Gastrointestinal Diseases Practice Questions

Q: What is the primary use of the combination of atropine and diphenoxylate?

Diarrhea. ***Diarrhea*** - The combination of **diphenoxylate** (an opioid receptor agonist) and a **small amount of atropine** is primarily used to treat diarrhea. - **Diphenoxylate** reduces gut motility, while **atropine** is added to discourage abuse by causing unpleasant anticholinergic side effects at higher doses. *Glaucoma* - **Atropine** is contraindicated in patients with **glaucoma** due to its mydriatic effect, which can worsen angle-closure glaucoma. - The combination is not used to treat glaucoma; glaucoma treatments aim to reduce intraocular pressure. *Iridocyclitis* - **Atropine** can be used in iridocyclitis as a **cycloplegic agent** to prevent synechiae formation and relieve pain. - However, **diphenoxylate** has no role in the treatment of iridocyclitis, making the combination inappropriate for this condition. *Nausea and vomiting* - Some anticholinergic drugs can be used for nausea and vomiting, such as **scopolamine**, but **atropine** is not a primary antiemetic in this context. - **Diphenoxylate**'s primary action is on gut motility for diarrhea, not specifically for nausea and vomiting.

Q: In a clinical setting, for how long are H2 blockers typically prescribed for the treatment of duodenal ulcers?

6 weeks. ***6 weeks*** - H2 blockers are generally prescribed for **6 weeks** for healing uncomplicated duodenal ulcers, which provides adequate time for complete mucosal repair. - This duration is the standard recommendation in most pharmacology textbooks, balancing effective healing with minimizing prolonged medication use. - Studies show that **80-90% of duodenal ulcers heal within 4 weeks**, and extending to 6 weeks ensures complete healing in most cases. *4 weeks* - A 4-week course achieves healing in many duodenal ulcers, but may be insufficient for complete mucosal repair in all patients. - While frequently effective, the **healing rate** at 4 weeks (70-80%) is lower than at 6 weeks, with higher risk of early recurrence. *8 weeks* - An 8-week course exceeds the typical duration needed for uncomplicated duodenal ulcer healing with H2 blockers. - Such prolonged therapy is usually reserved for **complicated ulcers**, **giant ulcers (>2 cm)**, or when initial treatment response is inadequate. - Maintenance therapy for recurrent ulcers may extend to this duration, but not for initial standard treatment. *12 weeks* - A 12-week course is unnecessarily long for duodenal ulcer healing with H2 blockers and is not standard practice. - Extended treatment beyond 8 weeks is typically only considered for **refractory ulcers** that fail standard therapy or for long-term maintenance in specific cases. - Modern practice favors switching to proton pump inhibitors (PPIs) rather than prolonging H2 blocker therapy if healing is inadequate.

Q: Which of the following is the most common adverse effect of omeprazole?

Headache. ***Headache*** - **Headache** is the most frequently reported adverse effect of omeprazole and other proton pump inhibitors (PPIs), occurring in approximately 2-7% of patients. - While generally mild and self-limiting, it is the most common reason for patients to report side effects during PPI therapy. - Other common adverse effects include diarrhea, nausea, and abdominal pain, but headache remains the most prevalent. *Constipation* - Constipation can occur with omeprazole use, but it is less common than headache or diarrhea. - Gastrointestinal side effects like constipation typically occur in a smaller proportion of patients compared to headache. *Liver dysfunction* - Mild **transient elevation of liver enzymes** can occur with omeprazole, but clinically significant liver dysfunction is rare. - Routine monitoring of liver function is generally not required unless there is pre-existing hepatic impairment. *Upper gastrointestinal bleeding* - Omeprazole is used to **treat and prevent** upper gastrointestinal bleeding by reducing gastric acid secretion in conditions like peptic ulcers and erosive esophagitis. - It is a therapeutic agent for this condition, not a causative factor.

Q: Which of the following is a guanylate cyclase agonist used in irritable bowel syndrome?

Linaclotide. ***Linaclotide*** - **Linaclotide** is an oral guanylate cyclase-C agonist approved for treating **constipation-predominant irritable bowel syndrome (IBS-C)** and **chronic idiopathic constipation (CIC)** [1]. - It works by increasing intracellular and extracellular **cyclic guanosine monophosphate (cGMP)**, leading to increased fluid secretion into the intestinal lumen and accelerated transit [1]. *Lubiprostone* - **Lubiprostone** is a **chloride channel activator**, specifically type 2 chloride channels, which enhances intestinal fluid secretion [1]. - It is used for **IBS-C** and **CIC**, but its mechanism of action is distinct from guanylate cyclase agonism [1]. *Tegaserod* - **Tegaserod** is a **5-HT4 receptor partial agonist** that was previously used for IBS-C in women [2], [3]. - Its prokinetic effects are mediated through serotonin receptors, not guanylate cyclase pathways [2]. *Methyl naltrexone* - **Methyl naltrexone** is a **peripherally acting mu-opioid receptor antagonist** used to treat **opioid-induced constipation** in advanced illness [1]. - It specifically blocks the constipating effects of opioids without crossing the blood-brain barrier, thus avoiding reversal of central opioid analgesia.

Q: Octreotide is not the primary treatment in:

Glucagonoma. ***Glucagonoma*** - While Octreotide can be used in some cases of Glucagonoma, the primary treatment usually involves **surgical resection** of the tumor. - Its role is often as an **adjunctive therapy** for symptom control, especially for the characteristic rash (necrolytic migratory erythema) and diarrhea, rather than as the primary curative agent. *Variceal bleeding* - Octreotide is a **first-line therapy** for acute variceal bleeding due to its ability to induce splanchnic vasoconstriction. - This action **reduces portal pressure** and blood flow, thereby decreasing bleeding from esophageal varices. *Refractory diarrhea in AIDS* - Octreotide is an effective agent for managing **severe, refractory diarrhea** in patients with AIDS, particularly when conventional antidiarrheal agents fail. - It works by **inhibiting intestinal secretion** and motility, reducing stool output. *Carcinoid syndrome* - Octreotide is the **primary pharmaceutical treatment** for carcinoid syndrome, which is caused by the overproduction of serotonin and other vasoactive substances by neuroendocrine tumors. - It effectively **controls symptoms** such as flushing, diarrhea, and bronchospasm by inhibiting the release of these mediators.

Q: Drugs used for the treatment of acute variceal bleeding include all of the following except:

Desmopressin. ***Desmopressin*** - **Desmopressin (DDAVP)** is a synthetic analog of antidiuretic hormone (ADH) used primarily for conditions like **diabetes insipidus** and bleeding disorders due to its effect on factor VIII and von Willebrand factor. - It does **not directly reduce splanchnic blood flow** or portal pressure, which are the main pharmacological targets for acute variceal bleeding. *Octreotide* - **Octreotide** is a synthetic analog of **somatostatin** that reduces splanchnic blood flow and portal pressure, thereby decreasing variceal bleeding. - It is a **first-line pharmacological agent** for acute variceal hemorrhage. *Somatostatin* - **Somatostatin** is an endogenous hormone that causes **splanchnic vasoconstriction** and reduces portal pressure, making it effective in controlling variceal bleeding. - It has a very **short half-life**, which is why analogs like octreotide are more commonly used clinically. *Terlipressin* - **Terlipressin** is a **vasopressin analog** that causes splanchnic vasoconstriction, leading to a reduction in portal pressure and variceal blood flow. - It is effective in controlling **acute variceal bleeding** and improving survival.

Q: Which of the following is NOT an H2 receptor antagonist?

Esomeprazole. ***Esomeprazole***- **Esomeprazole** is a **proton pump inhibitor (PPI)**, which works by irreversibly blocking the H+/K+-ATPase pump in gastric parietal cells, thereby reducing acid secretion [1].- All other options listed are H2 receptor antagonists, making esomeprazole the correct answer as it is *not* an H2 blocker [1, 2].*Ranitidine*- **Ranitidine** is an **H2 receptor antagonist** that competitively blocks histamine from binding to H2 receptors on parietal cells, leading to decreased gastric acid secretion [2].- It was commonly used for conditions like GERD and peptic ulcers, though its use has been restricted due to contamination concerns.*Famotidine*- **Famotidine** is also an **H2 receptor antagonist** that works similarly to ranitidine by blocking H2 receptors on parietal cells to reduce acid production [2].- It is frequently used for managing conditions associated with excess stomach acid.*Cimetidine*- **Cimetidine** is the **first-generation H2 receptor antagonist** that competitively inhibits histamine binding at H2 receptors on gastric parietal cells [2].- While effective for acid suppression, it has more drug interactions and side effects compared to newer H2 antagonists due to its inhibition of cytochrome P450 enzymes.

Q: Which of the following drugs is least likely to cause peptic ulcers?

Cyclosporine. ***Cyclosporine*** - Cyclosporine is an **immunosuppressant** that primarily acts by inhibiting **calcineurin**, which reduces T-cell activation. It is **least likely** to cause peptic ulcers among the choices. - While it has various side effects, gastrointestinal irritation or peptic ulceration is not a prominent or direct adverse effect compared to other listed drugs. *KCl* - **Potassium chloride (KCl)**, particularly in solid tablet form, can cause **direct mucosal injury** and **ulceration** in the esophagus and stomach if it dissolves slowly or is taken without adequate water. - This is due to its **hyperosmolar** nature and potential for local high concentrations of potassium ions. *Diclofenac* - **Diclofenac** is a **non-steroidal anti-inflammatory drug (NSAID)** that inhibits **COX-1 and COX-2 enzymes**, leading to reduced prostaglandin synthesis. - Reduced prostaglandins diminish the stomach's protective mucous barrier and bicarbonate secretion, making it highly prone to **peptic ulcer formation** and gastrointestinal bleeding. *Clopidogrel* - **Clopidogrel** is an **antiplatelet drug** that inhibits **ADP-induced platelet aggregation**, increasing the risk of bleeding throughout the body, including the gastrointestinal tract. - While it doesn't directly cause ulcers through mucosal damage like NSAIDs or KCl, its antiplatelet effect significantly **increases the risk of gastrointestinal bleeding** from any existing erosions or ulcers, which can complicate peptic ulcer disease.

Q: What is the mechanism of action of Tegaserod?

5HT4 receptor agonist. ***5HT4 receptor agonist*** - Tegaserod is a **selective serotonin 5-HT4 receptor partial agonist** that facilitates the release of neurotransmitters. - This action **stimulates the peristaltic reflex** and intestinal secretion, thereby accelerating intestinal transit and alleviating symptoms of **irritable bowel syndrome with constipation (IBS-C)**. *5HT3 receptor antagonist* - **5-HT3 receptor antagonists** (e.g., ondansetron) are primarily used as **antiemetics** to prevent nausea and vomiting. - They work by blocking serotonin's action at 5-HT3 receptors in the gastrointestinal tract and the **chemoreceptor trigger zone** in the brain. *Dopamine D2 receptor antagonist* - **Dopamine D2 receptor antagonists** (e.g., metoclopramide) are used as **prokinetics** and antiemetics due to their ability to block dopamine's inhibitory effect on gastrointestinal motility. - They increase **gastric emptying** and intestinal transit, but this is not the primary mechanism of tegaserod. *NK1 receptor antagonist* - **Neurokinin-1 (NK1) receptor antagonists** (e.g., aprepitant) are primarily used for their **antiemetic properties**, particularly in chemotherapy-induced nausea and vomiting. - They block the action of **substance P** at the NK1 receptor, which is involved in the emetic reflex.

Q: Which of the following best describes the mechanism of action of Lubiprostone?

Chloride channel activator. ***Chloride channel activator*** - Lubiprostone is a **prostaglandin E1 derivative** that specifically activates **chloride channels (ClC-2)** on the apical membrane of intestinal epithelial cells. - This activation leads to an increase in **fluid secretion into the intestinal lumen**, softening stool and promoting bowel movements. *Chloride channel inhibitor* - Medications that inhibit chloride channels would likely **reduce fluid secretion** in the intestines, potentially worsening constipation. - This mechanism is **opposite** to the therapeutic effect of lubiprostone, which aims to increase fluid content in the stool. *Sodium channel activator* - Activating sodium channels in the intestine could lead to increased fluid absorption or altered electrolyte balance, but this is **not the primary mechanism** of action for lubiprostone. - Lubiprostone's effect is centered around **anion (chloride) secretion**, not direct sodium channel activation. *Sodium channel inhibitor* - Inhibiting sodium channels might reduce sodium absorption, potentially increasing luminal water, but this is **not how lubiprostone works**. - Lubiprostone specifically targets **chloride channels** to achieve its cathartic effect.

Question 1

What is the primary use of the combination of atropine and diphenoxylate?

Accepted Answer

Diarrhea

Answer

Iridocyclitis

Answer

Nausea and vomiting

Answer

Glaucoma

Question 2

In a clinical setting, for how long are H2 blockers typically prescribed for the treatment of duodenal ulcers?

Accepted Answer

6 weeks

Answer

4 weeks

Answer

8 weeks

Answer

12 weeks

Question 3

Which of the following is the most common adverse effect of omeprazole?

Accepted Answer

Headache

Answer

Constipation

Answer

Liver dysfunction

Answer

Upper gastrointestinal bleeding

Question 4

Which of the following is a guanylate cyclase agonist used in irritable bowel syndrome?

Accepted Answer

Linaclotide

Answer

Tegaserod

Answer

Methyl naltrexone

Answer

Lubiprostone

Question 5

Octreotide is not the primary treatment in:

Accepted Answer

Glucagonoma

Answer

Variceal bleeding

Answer

Refractory diarrhea in AIDS

Answer

Carcinoid syndrome

Question 6

Drugs used for the treatment of acute variceal bleeding include all of the following except:

Accepted Answer

Desmopressin

Answer

Somatostatin

Answer

Terlipressin

Answer

Octreotide

Question 7

Which of the following is NOT an H2 receptor antagonist?

Accepted Answer

Esomeprazole

Answer

Cimetidine

Answer

Ranitidine

Answer

Famotidine

Question 8

Which of the following drugs is least likely to cause peptic ulcers?

Accepted Answer

Cyclosporine

Answer

KCl

Answer

Diclofenac

Answer

Clopidogrel

Question 9

What is the mechanism of action of Tegaserod?

Accepted Answer

5HT4 receptor agonist

Answer

5HT3 receptor antagonist

Answer

Dopamine D2 receptor antagonist

Answer

NK1 receptor antagonist

Question 10

Which of the following best describes the mechanism of action of Lubiprostone?

Accepted Answer

Chloride channel activator

Answer

Chloride channel inhibitor

Answer

Sodium channel activator

Answer

Sodium channel inhibitor

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?